Interstitial (Nonidiopathic) Pulmonary Fibrosis Workup
- Author: Eleanor M Summerhill, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP more...
See the list below:
- Routine blood analysis and serum chemistries are of limited value, and findings generally are nonspecific.
- Serologic testing for rheumatologic disease or vasculitis (eg, antinuclear antibodies, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein, anticitrulline antibody, antineutrophil cytoplasmic antibodies, antiglomerular basement membrane) may be appropriate in specific cases, as may serum precipitins for common hypersensitivity antigens. ACE testing is not very specific or sensitive but may offer a confirmatory clue to the diagnosis of sarcoidosis.
See the list below:
- Chest radiography findings are frequently abnormal in patients with fibrotic lung disease.
- Reticular and/or nodular opacities are the hallmark (see image below).
- Honeycombing is a late finding and correlates with severe histopathologic findings.
- Findings may be normal in 10% of patients with histologically proven disease. Therefore, a complete evaluation including pulmonary function testing and, in some cases, pulmonary exercise testing, should be undertaken in all patients clinically suspected to have underlying interstitial lung disease.
- Certain patterns and distributions of abnormality are suggestive of particular diseases.
- Sarcoid-associated interstitial disease often demonstrates symmetric hilar adenopathy.
- IPF, asbestosis, and connective-tissue disease–related changes are most often basilar and peripheral in distribution.
- Radiation fibrosis is restricted to the previous radiation port but also may have upper lung zone predominance, as may sarcoidosis, PLCH, HSP, pneumoconioses, and drug-related DPLD due to gold or nitrofurantoin therapy.
- Some patterns of abnormality, such as reverse congestive heart failure or a bat-wing pattern, are described with eosinophilic pneumonia.
- High-resolution chest CT scanning is more sensitive than chest radiography and may reveal characteristic, if not diagnostic, findings (see image below).[3, 4]High-resolution chest CT scan of patient with bilateral reticular and nodular interstitial infiltrates with upper zone predominance.See the list below:
- Linear reticular opacities are the most common findings.
- A ground-glass pattern is less common. It is an opacification that does not obscure underlying lung markings and is thought to be a favorable prognostic finding.
- Airspace consolidation may be present in eosinophilic pneumonia and COP.
- The presence of nodules suggests HSP, granulomatous disease (eg, sarcoidosis), PLCH, and RBILD.
- Large cystic spaces may be seen in PLCH and LAM.
- Honeycombing is indicative of end-stage disease and carries a poor prognosis.
See the list below:
- Pulmonary function testing may demonstrate reduced lung volumes with testing of total lung capacity, forced expiratory volume in 1 second, and forced vital capacity.
- The ratio of forced expiratory volume in 1 second to forced vital capacity is usually normal or increased.
- Diffusing capacity for carbon monoxide (DLCO) is generally reduced.
- Static pulmonary compliance is reduced.
- The restrictive defect may be absent in patients with significant smoking history due to coexistent chronic obstructive pulmonary disease.
- An obstructive defect may be present in patients with coexistent chronic obstructive pulmonary disease, sarcoidosis, LAM, and tuberous sclerosis.
- Arterial blood gas analysis often reveals an increased alveolar-arterial partial pressure of oxygen gradient and a reduced partial pressure of oxygen.
- Oxygen desaturation is common.
- All of these findings may be worsened with exercise.
- Pulmonary exercise testing may demonstrate decreased exercise capacity with exercise-limiting impairments in ventilation and gas exchange.
See the list below:
- Bronchiolar lavage findings are frequently abnormal although generally not diagnostic. Bronchiolar lavage is useful in evaluating the possibility of infection or malignancy. It can also be diagnostic for eosinophilic pneumonia.
- Transbronchial and endobronchial lung biopsies may be diagnostic, particularly for sarcoidosis or lymphangitic spread of carcinoma but frequently are not useful for other diagnoses. This is due to the patchy distribution of the majority of these diseases.
- Many patients require open or thoracoscopic lung biopsy to establish a definitive diagnosis. Currently, video-assisted thoracoscopic lung biopsy is the preferred method.
- The role of lung biopsy in the setting of high-resolution CT scan findings characteristic of specific disease entities remains controversial, with expert opinion weighing in on both sides.[3, 4, 6] Consensus appears to be building on the side of forgoing biopsy when the typical clinical and high-resolution CT scan features of UIP/IPF are present.
The histopathology observed in diffuse interstitial diseases of the lung is varied. The histopathologic classification of idiopathic interstitial pneumonias were updated by Katzenstein and Myers in 1998 to include the following 4 subgroups: UIP, AIP (diffuse alveolar damage), DIP/RBILD, and NSIP. Different histopathologic patterns may also be found in biopsy samples from different regions of the lung in these patients, particularly those with NSIP. Sometimes interstitial lung diseases with known etiologies may manifest one of the preceding histopathologic patterns. In addition, other pathologic patterns may be found. These may be consistent with COP, granulomatous lung disease, HSP, giant cell pneumonitis (hard-metal pneumoconiosis), eosinophilic pneumonia, and LIP (lymphoproliferative disorder).
Interpretation of histopathologic findings may be difficult, even in experienced hands, and disagreement may occur even among expert pathologists. In 2005, a 52% rate of disagreement between local general pathologists and "expert" pathologists was documented in a retrospective analysis.
Pulmonary function studies and the 6-minute walk study have demonstrated prognostic utility in IPF with histopathologic findings of UIP and NSIP. A diminished diffusion capacity (DLCO) on initial evaluation is a poor prognostic indicator, regardless of histologic type. Egan et al have proposed a classification scheme of advanced versus limited disease based on a cutoff value of DLCO greater or less than 40%. Similarly, a trough saturation of less than 88% during a 6-minute walk study has been shown to confer a worse prognosis. Serial decrements in functional vital capacity and DLCO over time are also associated with increased mortality.
Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994 Oct. 150(4):967-72. [Medline].
Seibold MA, Smith RW, Urbanek C, Groshong SD, Cosgrove GP, Brown KK, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One. 2013. 8(3):e58658. [Medline]. [Full Text].
Elliot TL, Lynch DA, Newell JD Jr, Cool C, Tuder R, Markopoulou K, et al. High-resolution computed tomography features of nonspecific interstitial pneumonia and usual interstitial pneumonia. J Comput Assist Tomogr. 2005 May-Jun. 29(3):339-45. [Medline].
Lynch DA, David Godwin J, Safrin S, Starko KM, Hormel P, Brown KK, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005 Aug 15. 172(4):488-93. [Medline].
Borie R, Quesnel C, Phin S, Debray MP, Marchal-Somme J, Tiev K, et al. Detection of alveolar fibrocytes in idiopathic pulmonary fibrosis and systemic sclerosis. PLoS One. 2013. 8(1):e53736. [Medline]. [Full Text].
Hunninghake GW, Zimmerman MB, Schwartz DA, King TE Jr, Lynch J, Hegele R, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001 Jul 15. 164(2):193-6. [Medline].
Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998 Apr. 157(4 Pt 1):1301-15. [Medline].
Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004 Jun. 59(6):500-5. [Medline].
Lettieri CJ, Veerappan GR, Parker JM, Franks TJ, Hayden D, Travis WD, et al. Discordance between general and pulmonary pathologists in the diagnosis of interstitial lung disease. Respir Med. 2005 Nov. 99(11):1425-30. [Medline].
Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax. 2005 Apr. 60(4):270-3. [Medline].
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004 Jan 8. 350(2):125-33. [Medline].
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005 May 1. 171(9):1040-7. [Medline].
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005 Nov 24. 353(21):2229-42. [Medline].
King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 Jan 1. 177(1):75-81. [Medline].
Kim R, Meyer KC. Therapies for interstitial lung disease: past, present and future. Ther Adv Respir Dis. 2008 Oct. 2(5):319-38. [Medline].
Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. 2005 Sep. 11(5):461-6. [Medline].
Mason DP, Brizzio ME, Alster JM, McNeill AM, Murthy SC, Budev MM, et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg. 2007 Oct. 84(4):1121-8. [Medline].
Meyer DM, Edwards LB, Torres F, Jessen ME, Novick RJ. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg. 2005 Mar. 79(3):950-7; discussion 957-8. [Medline].
Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004 Aug. 91 Suppl 2:S3-10. [Medline].
American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002 Jan 15. 165(2):277-304. [Medline].
King TE Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005 Aug 1. 172(3):268-79. [Medline].
King TE Jr, Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001 Sep 15. 164(6):1025-32. [Medline].
King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001 Oct 1. 164(7):1171-81. [Medline].
Martinez FJ, Keane MP. Update in diffuse parenchymal lung diseases 2005. Am J Respir Crit Care Med. 2006 May 15. 173(10):1066-71. [Medline].
Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med. 2002 Nov 1. 166(9):1235-9. [Medline].
Quigley M, Hansell DM, Nicholson AG. Interstitial lung disease--the new synergy between radiology and pathology. Histopathology. 2006 Oct. 49(4):334-42. [Medline].
Schwarz MI, King TE, Raghu G. Approach to the evaluation and diagnosis of interstitial lung disease. King TE, Schwarz MI, eds. Interstitial Lung Disease. Ontario, Canada: BC Decker; 2003. 1-30.